Objective  To provide evidence-based recommendations for reducing drug costs and minimizing drug wastage in anti-tumor treatment within the Chinese healthcare system.

Methods   By summarizing and analyzing the current situation of international research on dose rounding of anti-tumor drugs and the corresponding drug cost management strategy, combined with the present landscape of anti-tumor drug utilization in Chinese medical institutions, this study proposeed suggestions for cost control of anti-tumor drugs.

Results  Globally, various management strategies had been implemented to manage anti-tumor costs in healthcare settings, such as establishing dose ranges, dose bands, and dose rounding standards for anti-tumor drugs. Prescribed doses of intravenous antitumor drugs should be rounded to the nearest 10.0% of the drug's minimum packaging unit, in order to reduce the use of partial vials, achieve the goal of savings in therapeutic costs and reducing medication wastage.

Conclusion  By conducting dose rounding studies, Chinese medical institutions can establish dose rounding standards and protocols for anti-tumor drugs. These will provide references for minimizing the cost of anti-tumor drugs and drug wastage.

1.艾昆纬. 中国药品市场支出规模（2014-2028年）[EB/ OL]. (2024-02-28) [2025-04-15]. http://www.szyy.com.cn/sys-nd/1472.html.

2.沙利文. 中国创新生物药市场研究报告[EB/OL]. (2021-03-15) [2025-04-15]. https://www.frostchina.com/content/insight/detail?id= 62f21a1d3a1cb46c9a9fd5c8.

3.Hong SJ, Li EC, Matusiak LM, et al. Spending on antineoplastic agents in the United States, 2011 to 2016[J]. J Oncol Pract, 2018, 14(11): JOP1800069. DOI: 10.1200/JOP.18.00069.

4.Lien K, Cheung MC, Chan KK. Adjusting for drug wastage in economic evaluations of new therapies for hematologic malignancies: a systematic review[J]. J Oncol Pract, 2015, 12: e369-e379. DOI: 10.1200/JOP.2015.005876.

5.Fulsoundar R, Kadhe N, Patil S, et al. Quantifying drug wastage and economic loss of chemotherapy drugs at an adult oncology care of a tertiary care public hospital in India[J]. Cureus, 2023, 15(11): e49242. DOI: 10.7759/cureus.49242.

6.国家卫生健康委. 《关于印发节约药品资源遏制药品浪费实施方案的通知》（国卫医政发〔2023〕40号）[EB/ OL]. (2023-12-18) [2025-04-15]. https://www.gov.cn/zhengce/zhengceku/202312/content_6923589.htm.

7.任灵芝, 王婷, 余文浩, 等. 基于国际昂贵抗肿瘤药物剂量舍入倡议对我国抗肿瘤药物成本节约研究[J]. 中国医院药学杂志, 2025, 45(6): 701-705. [Ren LZ, Wang T, Yu WH, et al. Research on cost saving of anti-neoplastic drugs in China based on international expensive anti-neoplastic drug dose rounding initiative[J]. Chinese Journal of Hospital Pharmacy, 2025, 45(6): 701-705.] DOI: 10.13286/j.1001-5213.2025.06.15.

8.Shah VS, Irvine C, McWilliams RR, et al. Reducing cancer drug cost: 3-year analysis of automated dose rounding in electronic health records[J]. JCO Oncol Pract, 2024, 5: OP2300688. DOI: 10.1200/OP.23.00688.

9.Graff JM, Cramer J, Kolb LL, et al. Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution[J]. J Oncol Pharm Pract, 2024, 30(4): 705-709. DOI: 10.1177/10781552231184583.

10.Trovato A, Tyler LS, Nickman NA, et al. Interventions to reduce waste and improve billing compliance with medications in single-dose vials[J]. Am J Health Syst Pharm, 2023, 80(4): 222-226. DOI: 10.1093/ajhp/zxae230.

11.Shah V, Spence A, Bartels T, et al. Decreasing drug waste, reducing drug costs, and improving workflow efficiency through the implementation of automated chemotherapy dose rounding rules in the electronic health record system[J]. Am J Health Syst Pharm, 2022, 79(8): 676-682. DOI: 10.1093/ajhp/zxab479.

12.Dela-Pena JC, Eschenburg KA, LaRocca VW, et al. Financial impact of an automated oncology dose-rounding initiative: one-year analysis[J]. JCO Clin Cancer Inform, 2021, 5: 805-810. DOI: 10.1200/CCI.21.00024.

13.Rashed AN, Tomlin S, Arenas-López S, et al. Evaluation of the practice of dose-rounding in paediatrics[J]. Int J Pharm Pract, 2020, 28(1): 107-110. DOI: 10.1111/ijpp.12549.

14.Park JJ, Boutillier L, Cruz JE, et al. Effect of standardized infliximab dose rounding on an outpatient infusion center[J]. J Manag Care Spec Pharm, 2018, 24(10): 1028-1033. DOI: 10.18553/jmcp.2018.24.10.1028.

15.Chillari KA, Southward J, Harrigan N. Assessment of the potential impact of dose rounding parenteral chemotherapy agents on cost savings and drug waste minimization[J]. J Oncol Pharm Pract, 2018, 24(7): 507-510. DOI: 10.1177/1078155217722205.

16.Lindsey S, Parsons LB, Figg LR, et al. Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding[J]. J Oncol Pharm Pract, 2018, 24(1): 47-55. DOI: 10.1177/1078155216675518.

17.Vandyke TH, Athmann PW, Ballmer CM, et al. Cost avoidance from dose rounding biologic and cytotoxic antineoplastics[J]. J Oncol Pharm Pract, 2017, 23(5): 379-383. DOI: 10.1177/1078155216639756.

18.Ibrahim N. Global initiative to establish and implement dose rounding policy for expensive cancer therapy[J]. J Pharm Care Health Syst, 2018, 5: 1-2. DOI: 10.4172/2376-0419.1000e147.

19.Fahrenbruch R, Kintzel P, Bott AM, et al. Dose rounding of biologic and cytotoxic anticancer agents: a position statement of the hematology/oncology pharmacy association[J]. J Oncol Pract, 2018, 14(3): e130-e136. DOI: 10.1200/JOP.2017.025411.

20.Johnson KB, Ho YX, Andrew Spooner S, et al. Assessing the reliability of an automated dose-rounding algorithm[J]. J Biomed Inform, 2013, 46(5): 814-821. DOI: 10.1016/j.jbi.2013.06.002.

21.Sanyal A, Woelich SK, Mattila M, et al. Cost avoidance from automated dose rounding of biological and cytotoxic anticancer drugs in an integrated delivery network[J], Blood, 2020, 136(1): 10-11. DOI: 10.1182/blood-2020-141586.

22.Jenkins P, Wallis R. Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity[J]. J Oncol Pharm Pract, 2010, 16(4): 251-255. DOI: 10.1177/1078155209351304.

23.Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690.

24.Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma[J]. J Clin Oncol, 2008, 26(36): 5950-5956. DOI: 10.1200/JCO.2008.16.1927.

25.Alwhaibi AM, Alshamrani AA, Alenazi MA, et al. Vincristine-induced neuropathy in patients diagnosed with solid and hematological malignancies: the role of dose rounding[J]. J Clin Med, 2023, 12(17): 5662. DOI: 10.3390/jcm12175662.

26.张婧, 李高洁, 蒋茜, 等. 美国药品成本管理策略对我国医疗机构药品费用控制启示[J]. 中国医院药学杂志, 2020, 40(12): 1303-1306. [Zhang J, Li GJ, Jiang X, et al. Enlightenment of ASHP strategies on medication cost management for medical institutions in China[J]. Chinese Journal of Hospital Pharmacy, 2020, 40(12): 1303-1306.] DOI: 10.13286/j.1001-5213.2020.12.05.

27.张杰, 张永凯, 宋燕青. 某院静脉输液非整支用量药品对患者费用的影响分析[J]. 中国医院药学杂志, 2017, 37(20): 2085-2088. [Zhang J, Zhang YK, Song YQ. Analysis of the influence of non-whole medication administration through intravenous infusion on patient costs[J]. Chinese Journal of Hospital Pharmacy, 2017, 37(20): 2085-2088.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2017.20.18.

28.刘慧, 闫峻峰, 朱九群, 等. 通过优化药品规格减少静脉化疗药物浪费的效果分析[J]. 中国药物应用与监测, 2022, 19(6): 409-412. [Liu H, Yan JF, Zhu JQ , et al. Effect analysis of reducing waste of intravenous chemotherapy drugs by optimizing drug specification[J]. Chinese Journal of Drug Application and Monitoring, 2022, 19(6): 409-412.] DOI: 10.3969/j.issn.1672-8157.2022.06.015.

29.El Baraka S, Cherif Chefchaouni A, Bourdaime A, et al. Evaluating cost savings in cytotoxic leftover management: a prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology[J]. J Oncol Pharm Pract, 2024, 30(7): 1152-1159. DOI: 10.1177/10781552231203403.

30.Gilbar PJ, Chambers CR, Musicco F. Preventing drug vial wastage and reducing expenditure associated with injectable cancer drugs: international oncology pharmacy survey[J]. J Oncol Pharm Pract, 2022, 28(6): 1332-1339. DOI: 10.1177/10781552211024723.